Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine

Article English OPEN
Shi, Gao-Na ; Zhang, Chuang-Nian ; Xu, Rong ; Niu, Jin-Feng ; Song, Hui-Juan ; Zhang, Xiu-Yuan ; Wang, Wei-Wei ; Wang, Yan-Ming ; Li, Chen ; Wei, Xiao-Qing ; Kong, De-Ling (2017)
  • Publisher: Elsevier
  • Related identifiers: doi: 10.1016/j.biomaterials.2016.10.047
  • Subject: RK
    mesheuropmc: nervous system diseases | therapeutics | health care economics and organizations | technology, industry, and agriculture

Whole tumor cell lysates (TCL) have been implemented as tumor antigens for cancer vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy remain unsatisfactory. In order to improve the efficacy of TCL-based vaccines, biomaterials have been employed to enhance antigen delivery and presentation. Here, we have developed chitosan nanoparticles (CTS NPs) with surface mannose (Man) moieties for specific dendritic cells (DCs) targeting (Man-CTS NPs). The Man-CTS NPs were then loaded with TCL generated from B16 melanoma cells (Man-CTS-TCL NPs) for in vitro and in vivo assessment. Potency of the Man-CTS-TCL NPs as cancer vaccine was also assessed in vivo by immunization of mice with Man-CTS-TCL NPs followed by re-challenge with B16 melanoma cell inoculation. We have shown here that Man-CTS-TCL NPs promote bone marrow-derived dendritic cells (BMDCs) maturation and antigen presentation in vitro. In vivo evaluation further demonstrated that the Man-CTS-TCL NPs were readily taken up by endogenous DCs within the draining lymph node (DLN) following subcutaneous administration accompanied by increasing in serum IFN-γ and IL-4 levels. Tumor growth was also significantly delayed in mice primed with Man-CTS-TCL NPs vaccine, attributable at least in part to cytotoxic T lymphocytes response. Moreover, Man-CTS-TCL NPs vaccine also exhibited therapeutic effects in mice with melanoma. Thus, we report here the Man-CTS-TCL NPs as effective anti-tumor vaccine for cancer immunotherapy.
  • References (10)

    [1] S.B. Coffelt, K.E. de Visser, Immune-mediated mechanisms influencing the efficacy of anticancer therapies, Trends Immunol. 36 (2015) 198-216.

    [2] A.S. Cheung, D.J. Mooney, Engineered materials for cancer immunotherapy, Nano today 10 (2015) 511-531.

    [3] A.Milani, D. Sangiolo, F. Montemurro, M. Aglietta, G. Valabrega, Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives, Ann. Oncol. 24 (2013) mdt133.

    [4] K. Palucka, J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines, Immunity 39 (2013) 38-48.

    [5] I. Melero, G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, et al., Therapeutic vaccines for cancer: an overview of clinical trials, Nat. Rev. Clin. Oncol. 11 (2014) 509-524.

    [6] J. Banchereau, A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer, Nat. Rev. Immunol. 5 (2005) 296-306.

    [7] S.T. Reddy, M.A. Swartz, J.A. Hubbell, Targeting dendritic cells with biomaterials: developing the next generation of vaccines, Trends Immunol. 27 (2006) 573-579.

    [8] J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature 392 (1998) 245-252.

    [9] F.O. Nestle, J. Banchereau, D. Hart, Dendritic cells: on the move from bench to bedside, Nat. Med. 7 (2001) 761-765.

    [10] E. Segura, J.A. Villadangos, Antigen presentation by dendritic cells in vivo, Curr. Opin.

  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    43
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    Online Research @ Cardiff - IRUS-UK 0 43
Share - Bookmark